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Introduction
Carpal tunnel syndrome (CTS) is a compression neu-
ropathy of the median nerve at the wrist. Any condition
that reduces the size of the carpal tunnel or increases the
volume of its content will cause compression of the me-
dian nerve. Symptoms of CTS include (nocturnal) pain,
paraesthesias and hypaesthesias in the hand, in the area
innervated by the median nerve. The estimated preva-
lence of clinically and electrophysiologically confirmed
CTS in the general population is 2.7 % [3].
To relieve the pressure on the median nerve (directly
or indirectly), several treatment options, both surgical
and conservative, are available. The most common con-
servative measures for the initial treatment of CTS are
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 Abstract Carpal tunnel syn-
drome (CTS) is a common disor-
der, for which various conservative
treatment options are available.
The objective of this study is to de-
termine the efficacy of the various
conservative treatment options for
relieving the symptoms of CTS.
Computer-aided searches of MED-
LINE (1/1966 to 3/2000), EMBASE
(1/1988 to 2/2000) and the
Cochrane Controlled Trials Regis-
ter (2000, issue 1) were conducted,
together with reference checking.
Included were randomised con-
trolled trials evaluating the efficacy
of conservative treatment options
in a study population of CTS pa-
tients, with a full report published
in English, German, French or
Dutch. Two reviewers indepen-
dently selected the studies. Four-
teen randomised controlled trials
were included in the review. Assess-
ment of methodological quality
and data-extraction was indepen-
dently performed by two reviewers.
A rating system, based on the num-
ber of studies and their method-
ological quality and findings, was
used to determine the strength of
the available evidence for the effi-
cacy of the treatment. Diuretics,
pyridoxine, non-steroidal anti-in-
flammatory drugs, yoga and laser-
acupuncture seem to be ineffective
in providing short-term symptom
relief (varying levels of evidence)
and steroid injections seem to be
effective (limited evidence). There
is conflicting evidence for the effi-
cacy of ultrasound and oral
steroids. For providing long-term
relief from symptoms there is lim-
ited evidence that ultrasound is ef-
fective, and that splinting is less ef-
fective than surgery. In conclusion,
there is still little known about the
efficacy of most conservative treat-
ment options for CTS. To establish
stronger evidence more high qual-
ity trials are needed.
 Key words Conservative
therapeutics · Carpal tunnel
syndrome · Review literature ·
Randomised controlled trials
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local and systemic steroids, non-steroidal anti-inflam-
matory drugs (NSAIDs), diuretics, pyridoxine and
wrist-splints [12,37]. In addition,yoga,chiropractics,ul-
trasound and laser treatment has been advocated. How-
ever, convincing evidence of the efficacy of these con-
servative treatment options has not yet been
established.
Inflammation of the flexor tenosynovium (non-spe-
cific or due to rheumatoid arthritis) causes thickening of
the synovium which, in time,may result in median nerve
compression. Treatment with injections of cortico-
steroids into the carpal tunnel and the prescription of
systemic steroids are both intended to reduce this
tenosynovitis [35]. NSAIDs provide pain relief, and also
suppress inflammation [7]. Oral diuretics reduce
oedema in the carpal tunnel (accompanying pregnancy
and inflammation) [30]. Some researchers consider that
a deficiency of pyridoxine (vitamin B6) causes CTS, and
therefore supplemental oral pyridoxine is prescribed
[16]. Others, however, suggest that the positive response
to pyridoxine in CTS patients may actually be related to
an unrecognised peripheral neuropathy (commonly as-
sociated with diabetes mellitus) [6]. Immobilisation of
the wrist in a neutral position with a splint maximises
carpal tunnel volume and minimises pressure on the
median nerve [21]. Stretching of the arm, hand and fin-
gers (yoga postures) possibly has a similar effect [19].
The contribution of manual therapy (chiropractics) in
the healing process of CTS is not known [18]. Ultra-
sound is assumed to have thermal effects on the target
tissue resulting in an increase in blood flow, local me-
tabolism and tissue regeneration, and also reducing in-
flammation, oedema and pain [5], thereby facilitating
the recovery of nerve compression. The non-thermal ef-
fects of laser presumably promote tissue healing in a
similar way, but the underlying mechanism is still un-
clear [4].
The objective of this systematic review was to deter-
mine the short and long-term efficacy of the various
conservative treatment options for relieving the symp-
toms of CTS.
Methods
 Search and selection of studies
To identify publications, a search was made in MEDLINE (1/1966 to
3/2000), EMBASE (1/1988 to 2/2000) and the Cochrane Controlled
Trials Register (2000, issue 1). A generic search for randomised con-
trolled trials (RCTs) was made [11], combined with a specific search
for CTS (using the keywords carpal tunnel syndrome, carp$ tunn$,
carp$ syndr$, and tunn$ syndr$). In addition, the reference lists of all
relevant publications were checked.
A study was included in the review if the following criteria were
met: 1) the study population consisted of patients with CTS; 2) the ef-
ficacy of one or more conservative treatment options was evaluated;
3) the study was designed as a randomised controlled trial; 4) the re-
sults were published as a full report, written in English, German,
French or Dutch.
Studies were selected by two reviewers (AG, RS) independently
and disagreements were discussed to reach consensus.
 Assessment of methodological quality
Two reviewers (AG, MdK) independently assessed the methodologi-
cal quality of all selected studies. Disagreements between the review-
ers were identified, and discussed until consensus was achieved. The
criteria list that was applied (Table 1) has been recommended by the
Cochrane Back Review Group for systematic reviews in the field of
musculoskeletal disorders [41]. This list was adapted for reviewing
conservative treatment options for CTS with regard to prognostic in-
dicators (c), description of interventions (d) and outcome measures
(j). The list consists of items on internal validity (b1, b2, c, e, f, g, h, i, l,
n, p), external validity (a, d1, d2, j, k, m1, m2) and statistical criteria (o,
q). Criteria could be scored as positive (‘yes’), negative (‘no’) or un-
clear (‘don’t know’). The quality score of the studies was based on the
number of positive scores for internal validity.
 Data-extraction
Data from the articles were extracted independently by two reviewers
(AG, MS) and recorded on a standardised form. Information was col-
lected on participants (age, gender, duration of symptoms, clinically
and/or electrophysiologically confirmed CTS, number of patients bi-
Table 1 Criteria list for the assessment of methodological quality of RCTs evaluat-
ing the efficacy of conservative treatment options for CTS*
Patient selection
a. Were the eligibility criteria specified?
b. Treatment allocation:
1) Was a method of randomisation applied?
2) Was the treatment allocation concealed?
c. Were the groups similar at baseline with regard to the most important
prognostic indicators?
Interventions
d. 1) Was the index intervention explicitly described?
2) Was/were the control intervention(s) explicitly described?
e. Was the care-provider blinded for the intervention?
f. Were co-interventions avoided or similar for all groups?
g. Was the compliance acceptable in all groups?
h. Was the patient blinded for the intervention?
Outcome measurement
i. Was the outcome assessor blinded for the intervention?
j. Were the outcome measures relevant?
k. Were side effects described?
l. Was the drop-out/loss to follow-up rate described and acceptable?
m. Timing follow-up measurements:
1) Was a short-term follow-up measurement performed?
2) Was a long-term follow-up measurement performed?
n. Was the timing of the outcome assessment similar for all groups?
Statistics
o. Was the sample size described for each group?
p. Did the analysis include an intention-to-treat analysis?
q. Were point estimates and measures of variability presented for the primary
outcome measures?
* All criteria were scored yes (+), no (–) or don’t know (?).
Criteria are related to internal validity (b1, b2, c, e, f, g, h, i, l, n, p), external validity
(a, d1, d2, j, k, m1, m2) or statistics (o, q).
The operationalization of the criteria is available from the authors on request
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laterally treated, number of patients or hands randomised), interven-
tions (type, treatment schedule),outcome measures, timing of the fol-
low-up measurements, and results (point estimates and measures of
variability, number of patients or hands). Although data on all re-
ported outcomes were extracted, outcome measures on symptoms
(e. g. pain, percentage of patients with improved symptoms) were
considered as primary outcomes,because these are of the greatest im-
portance for patients [23, 27]. Information on side-effects was also
recorded.
 Statistical analysis
The quantitative analysis (meta-analysis) was limited to studies that
were clinically homogeneous, i. e. for which the participants, inter-
ventions, outcome measures and timing of the follow-up measure-
ments were considered to be similar.Study results were combined,us-
ing a fixed effects model,or a random effects model if the studies were
statistically heterogeneous. For studies that were clinically heteroge-
neous, or did not present the data in sufficient detail to enable statis-
tical pooling, a qualitative analysis was performed. In that case a rat-
ing system was used, consisting of four levels of evidence, based on
the number of studies, their methodological quality and their find-
ings [42]:
Level 1. Strong evidence – provided by generally consistent findings
in multiple high quality RCTs.
Level 2. Moderate evidence – provided by generally consistent find-
ings in one high quality RCT and one or more low quality
RCTs, or by generally consistent findings in multiple low
quality RCTs.
Level 3. Limited or conflicting evidence – only one RCT (either high
or low quality) or inconsistent findings in multiple RCTs, re-
spectively.
Level 4. No evidence – no RCTs.
Conclusions (positive, negative or neutral) with regard to the
findings of the studies were based on the statistical significance (p <
0.05) of the outcome measures on symptoms as assessed by the re-
viewers. Both short-term (≤ 3 months) and long-term (> 3 months)
results were considered. If at least 75 % of the studies had a similar
conclusion,the findings were considered to be consistent.An RCT was
(arbitrarily) considered to be of high quality if at least 6 of the 11 in-
ternal validity criteria were scored positive.A sensitivity analysis was
performed to examine the results when high quality was defined as
scoring 5 or more, or 7 or more of the internal validity criteria posi-
tive.
Results
 Search and selection of studies
Fourteen publications met the inclusion criteria, 11 of
which were found in MEDLINE. Searching EMBASE and
the Cochrane database resulted in the identification of 1
and 2 additional publications, respectively. No extra
publications were found by reference checking.
 Methodological quality
Initially, the two reviewers agreed on 68 % of the
methodological quality criteria. Almost all disagree-
ments were due to reading errors (81 %) and the rest to
differences in interpretation (19 %). After discussion, all
disagreements were resolved. The results of the
methodological quality assessment are shown in Table
2. Seven of the 14 studies were of high quality. Many
studies reported on random treatment allocation, but
failed to describe the exact procedure (b1) or state
whether the method of randomisation was concealed
(b2).Also, information on co-interventions (f) and com-
pliance (g) was often lacking. The most prevalent
methodological shortcomings were that the study
groups were not similar at baseline (c), that the care-
provider was not blinded (or that this was not men-
tioned) (e), that the drop-out/loss to follow-up rate was
unacceptably high (l) and that no intention-to-treat
analyses was performed (or this was unclear) (p). Fur-
thermore, side effects often were not described (k) and
the majority of the studies did not include a long-term
follow-up measurement (m2).
 Efficacy of the conservative treatment options
Data from the trials were not statistically pooled, be-
cause studies were clinically heterogeneous with regard
to participants (different inclusion/exclusion criteria),
interventions and outcome measures (different symp-
toms measured). Furthermore, there was often only one
study that evaluated a certain intervention or compari-
son of interventions,and the presentation of the data did
not always make pooling possible. Instead, all the con-
clusions with regard to the efficacy of the conservative
treatment options were based on the strength of the
available evidence according to the pre-defined rating
system.
The conclusions of the studies with regard to short-
and long-term symptoms are shown in Table 2. Table 3
presents the study characteristics (participants, inter-
ventions and results).
Steroid injections
Three studies, 2 high quality and 1 low quality, were
identified. One high quality RCT [9] assessed the effect
of a steroid injection proximal to the carpal tunnel. Af-
ter 1 month significantly more participants had im-
proved in the intervention group than in the control
group. After 3 months, however, only the participants
who had improved after 1 month were asked if they
needed further treatment. Therefore no conclusion can
be drawn with regard to the difference in long-term im-
provement in symptoms between the groups [24]. The
other high quality RCT [32] compared a local steroid in-
jection (into the carpal tunnel) with an intramuscular
steroid injection. The local injection provided symptom
relief for significantly more patients than the intramus-
cular injection (after 1 month). However, the long-term
difference between the groups could not be evaluated,
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Table 3 Characteristics of RCTs evaluating the efficacy of conservative treatment options for CTS
Reference Participants Interventions Results*
Steroid injections
Dammers [9] mean age 52 years, 83% female, mean (1) steroid injection (40 mg methylprednisolone, Improvement in symptoms in 77 % (1) and 20 %
duration of symptoms 29 months 10 mg lidocaine) proximal to the carpal tunnel (2) after 1 month (difference 57 % [95 % CI 36 to
clinical and electrophysiological CTS (n = 30 patients) 77] ). No side effects in either group.
(2) placebo injection (10 mg lidocaine)
(n = 30 patients)
Özdogan [32] mean age 46 years, 100 % female, (1) steroid injection (1.5 mg Celestone R) into the Improvement in symptoms in 50 % (1) and 16 %
mean duration of symptoms 38 months carpal tunnel and placebo injection (0.5 ml saline (2) after 1 month (difference 34 % [95 % CI 6 to
clinical CTS only Idiopathic CTS solution) into the deltoid muscle (same side) 63]).
(n = 18 patients)
(2) steroid injection (1.5 mg Celestone R) into the
deltoid muscle and placebo injection (0.5 ml saline
solution) into the carpal tunnel (same side)
(n = 19 patients)
Girlanda [22] mean age 45 years, 81 % female, (1) steroid injection (15 mg methylprednisolone Improvement in paraesthesias, nocturnal
mean duration of symptoms 53 months acetate) into the carpal tunnel, repeated after acroparaesthesias, pain and motor deficit after
clinical and electrophysiological CTS 1 week (n = 16 patients/27 hands) 1, 2, 4, 8 weeks in (1) versus improvement in
idiopathic CTS (2) placebo injection (15 mg saline solution) paraesthesias (after 1, 2 weeks), nocturnal
21 out of 32 patients bilaterally treated (n = 16 patients/26 hands) acroparaesthesias (after 1, 2, 4, 8 weeks) and pain
(after 1 week) in (2). Differences between the
groups were not evaluated. No side effects in
either group.
Ultrasound treatment
Ebenbichler [13] mean age 51 years, mean duration of (1) ultrasound 1.0 W/cm2 15 minutes/session Significantly more improvement in symptoms
symptoms 8 months 5 sessions/week for 2 weeks, 2 sessions/week for (pain, paraesthesias, sensory loss) in (1) versus
clinical and electrophysiological CTS 5 weeks (n = 45 hands) (2) after 2 and 7 weeks, and 8 months. No side
idiopathic CTS (2) placebo ultrasound 0 W/cm2 (n = 45 hands) effects in either group.
mild to moderate CTS
all patients (n = 34) bilaterally treated
Oztas [33] mean age 52 years, 100 % female, (1) ultrasound 1.5 W/cm2 5 minutes/session Improvement in pain, pain/paraesthesias at
mean duration of symptoms 84 months 5 sessions/week for 2 weeks (n = 10 hands) night/day, frequency of awakening at night in
clinical and electrophysiological CTS (2) ultrasound 0.8 W/cm2 5 minutes/session both groups after 20 days, but no significant
idiopathic CTS 5 sessions/week (n = 10 hands) differences between the groups.
12 out of 18 patients bilaterally treated (3) placebo ultrasound 0 W/cm2 (n = 10 hands)
Pyridoxine
Spooner [39] mean age 43 years, 63 % female (1) pyridoxine 200 mg/day for 12 weeks Improvement in swelling and movement
clinical and electrophysiological CTS (n = 18 patients) discomfort in (1) after 12 weeks, but no
idiopathic CTS (2) placebo tablets (n = 17 patients) significant differences in swelling, movement
discomfort, night discomfort and poor
co-ordination between the groups after 12 weeks.
Stransky [40] clinical and electrophysiological CTS (1) pyridoxine 200 mg/day for 10 weeks Improvement in symptoms in 50 % (2), 80 %
(n = 6 patients) (2) and 75 % (3) after 10 weeks, but no
(2) placebo tablets (n = 5 patients) significant differences between the groups.
(3) no treatment (n = 4 patients)
Other types of oral medication
Chang [8] mean age 46 years, 73 % female (1) diuretic (trichlormethiazide) 2 mg/day for Significantly more improvement in the mean
clinical and electrophysiological CTS 4 weeks (n = 20 patients) global symptom score (pain, numbness,
idiopathic CTS (2) NSAID-slow release (tenoxicam-slow release) paraesthesias, weakness/clumsiness, nocturnal
mild to moderate CTS 20 mg/day for 4 weeks (n = 22 patients) awakening) in (3) versus (4) after 4 weeks.
(3) steroid (prednisolone) 20 mg/day for 2 weeks, Minor side effects in 2 (1), 6 (2), 5 (3) and 3
10 mg/day for 2 weeks (n = 26 patients) (4) patients.
(4) placebo tablets (n = 23 patients)
Pal [34] mean age 47 years, 90 % female, (1) diuretic (bendrofluazide) 5 mg/day for No improvement in symptoms at all in 54 % (1)
median duration of symptoms 7 months 4 weeks (n = 23 patients/41 hands) and 50 % (2) after 4 weeks (difference 4 %
clinical and electrophysiological CTS (2) placebo tablets (n = 25 patients/40 hands) [95 % CI – 18 to 25]). 1 patient with side effects
idiopathic CTS in (1).
33 out of 48 patients bilaterally treated
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because some patients received extra injections, and the
moment of outcome assessment for them was different
to that for patients who received no additional treat-
ment. The low quality study [22] evaluated the efficacy
of local steroid therapy (into the carpal tunnel), but dif-
ferences in outcomes between the intervention group
and the placebo group were not evaluated.
There is therefore limited evidence (level 3) that a
steroid injection proximal to the carpal tunnel is more
effective than placebo in improving CTS symptoms in
the short-term (1 month). The same applies to a steroid
injection into the carpal tunnel, compared with an in-
tramuscular steroid injection.
Ultrasound treatment
The efficacy of ultrasound was assessed in 1 high qual-
ity and 1 low quality RCT. In the high quality study [13],
ultrasound treatment resulted in significantly more im-
provement in symptoms than ‘sham’ ultrasound in the
short-term (2 and 7 weeks) and in the long-term (8
months). In the low quality study [33],no differences be-
tween the groups were reported in the short-term (20
days).
There is conflicting evidence (level 3) that ultrasound
is more effective than placebo in relieving CTS symp-
toms in the short-term,and limited evidence (level 3) for
its long-term effectiveness.
Pyridoxine
In 1 high quality [39] and 1 low quality [40] RCT the ef-
fect of pyridoxine was evaluated. Neither study found
any significant differences in symptom improvement
between the treatment groups, indicating moderate evi-
dence (level 2) that pyridoxine and placebo are equally
effective.
Table 3 Characteristics of RCTs evaluating the efficacy of conservative treatment options for CTS (cont)
Reference Participants Interventions Results*
Herskovitz [25] mean age 50 years, 80 % female, mean (1) steroid (prednison) 20 mg/day for 1 week, Significantly more improvement in mean global
duration of symptoms 21 months 10 mg/day for 1 week (n = 8 patients) symptom score (pain, numbness, paraesthesias,
clinical and electrophysiological CTS (2) placebo tablets (n = 10 patients) weakness/clumsiness, nocturnal awakening) in
1 patient with rheumatoid arthritis, (1) versus (2) after 2 weeks, but no significant
2 patients with diabetes mellitus differences after 4 and 8 weeks. 3 patients with
mild to moderate CTS side effects in both groups.
Other treatment options
Davis [10] mean age 37 years, 59 % female (1) chiropractic care (manipulation of soft No outcomes on symptoms. 10 patients with
clinical and electrophysiological CTS tissues and bony joints of the upper extremities side effects in (2) and 1 patient in (1).
idiopathic CTS and spine) 3 treatments/week for 2 weeks,
58 out of 91 patients bilaterally treated 2 treatments/week for 3 weeks, 1 treatment/week
for 4 weeks, ultrasound 1.0–1.5 W/cm2 5 minutes
for half of the chiropractic treatment sessions,
nocturnal wrist supports (n = 45 patients)
(2) NSAID (ibuprofen) 3 x 800 mg/day for 1 week,
2 x 80 mg/day for 1 week, 800 mg as needed to a
maximum of 2400 mg/day for 7 weeks, nocturnal
wrist supports [n = 46 patients)
Garfinkel [19] mean age 49 years, 67 % female (1) yoga (11 yoga postures for strengthening, No significant differences in pain between the
clinical and electrophysiological CTS stretching, balancing each joint in the upper groups after 8 weeks. Improvement in sleep
idiopathic CTS body, and relaxation) 1–1.5 hours/treatment disturbance in 24 % (f) and 13 % (2) after
25 out of 42 patients bilaterally treated 2 treatments/week for 8 weeks (n = 22 patients/ 8 weeks (difference 11 % [95 % CI –14 to 36]).
35 hands completed study)
(2) current treatment and wrist splint offered
(n = 20 patients/32 hands completed study)
Aigner [1] mean age 54 years, 77 % female, mean (1) soft-laser light (Helium-Neon) 5 mV on Improvement in pain during the night in 100 %
duration of symptoms 29 months 6 acupuncture points 15 seconds/point (1) and 69 % (2) after end of treatment/before
clinical and electrophysiological CTS 2 treatments/week for 3 weeks (preoperative) operation (difference 31 % [95 % CI 6 to 56]).
(n = 13 patients) But no significant differences in improvement
(2) placebo laser acupuncture 0.5 V infra-red light in paraesthesias and activity-associated pain
(preoperative) (n = 13 patients) between the groups after end of treatment/
before operation.
Garland [20] mean age 47 years, 100 % female, mean (1) plaster-of-paris splinting of hand/wrist/arm Significantly more relief of symptoms in (2)
duration of symptoms 4 months for 1 month (n = 11 patients) versus (1) after 1 year. No side effects in
clinical and electrophysiological CTS (2) open operation (n = 11 patients) either group.
* results of the outcomes on symptoms. p-values < 0.05 were considered to be significant.
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Other types of oral medications
Two high quality studies and 1 low quality study were
found. One high quality RCT [8] assessed the efficacy of
a diuretic, a NSAID, and an oral steroid, compared to
placebo. Only the steroid group showed significantly
more improvement in symptoms than the placebo
group (after 4 weeks). In the other high quality RCT [34],
no differences were found between a group receiving a
diuretic and a placebo group (after 4 weeks). The long-
term differences between the groups could not be eval-
uated,because only patients who improved after 4 weeks
were assessed after 6 months. The low quality study [25]
evaluated the effect of an oral steroid.After 2 weeks there
was significantly more improvement in symptoms in the
steroid group,compared with the placebo group,but this
effect had disappeared after 4 and 8 weeks.
There is therefore strong evidence (level 1) and lim-
ited evidence (level 3), respectively, that diuretics and
NSAIDs are not more effective than placebo. There is
also conflicting evidence (level 3) that an oral steroid is
more effective than placebo in improving CTS symp-
toms in the short-term.
Other treatment options
The efficacy of chiropractic treatment (manipulation,
ultrasound, wrist support) was compared with medical
treatment (NSAID, wrist support) in 1 high quality RCT
[10], but no outcome measures focussing on symptoms
were included.
In 1 low quality study [19], a yoga-based regimen was
as effective in relieving CTS symptoms as ‘current treat-
ment’ (after 8 weeks). The control group did not receive
uniform treatment, as they continued with their ‘current
treatment’ (whatever that was), and were also offered a
wrist splint. The authors falsely report that they assessed
the efficacy of yoga compared with wrist splinting or no
treatment [28], because the results of the study only in-
dicate that there is limited evidence (level 3) that yoga is
not more effective than ‘current treatment’.
Only 1 low quality study [1] investigated whether
soft-laser acupuncture was beneficial in the pre-opera-
tive treatment of CTS. The laser group had significantly
more pain relief during the night, but did not have more
relief from paraesthesias and activity-associated pain.
Overall, there is limited evidence (level 3) that soft-laser
acupuncture is not more effective in relieving symptoms
than placebo.
Splinting was compared with surgery in 1 low quality
study [20]. No short-term follow-up measurement was
performed,but after 1 year splinting was found to be sig-
nificantly less effective than surgery in providing symp-
tom relief, indicating limited evidence (level 3).
 Sensitivity-analysis
Changing the cut-off point of the quality score to 5 or
more, and 7 or more positive internal validity criteria,
resulted in 10 and 4 high quality studies, respectively
(Table 2). However, there was only one change in the
level of evidence (from strong to moderate), namely that
diuretics were equally effective as placebo, if high qual-
ity was defined as a positive score on at least 7 of the in-
ternal validity criteria.
 Side-effects
No side-effects were reported for steroid injections 
[9, 22], ultrasound treatment [13] and splinting [20].
Minor side effects (e. g. nausea, abdominal discomfort,
headache) were reported for diuretics [8, 34], NSAIDs 
[8, 10] oral steroids [8, 25] and chiropractic treatment
[10]. There was no information about the side-effects of
pyridoxine, yoga or laser-acupuncture.
Discussion
 Search and selection of studies
Because a few restrictions were made in the search,some
studies could have been missed, which may have lead to
bias. Unpublished studies and studies which were pre-
sented only in an abstract are more likely to have non-
significant results [14, 36]. Furthermore, trials with sig-
nificant results are more likely to be published in English
[15].
 Methodological quality
There is no consensus on which criteria list should be
used for assessing the methodological quality of RCTs.
However, the criteria that are regarded as being most
important in reducing bias, concealment of allocation
and double-blinding,are included in the list used for this
review [38].The other criteria in the list are generally ac-
cepted methodological criteria that are also included in
most of the other available lists [31]. In fact, the focus
was on the quality of the reporting. It is possible that a
trial did meet a certain criterion, but that for the sake of
conciseness this aspect was not described in detail in the
publication.
One drawback of combining information on diffe-
rent study characteristics related to internal validity into
a sum-score for methodological quality is, that a positive
score on one criterion might compensate a negative
score on another. Therefore, a sum-score could conceal
methodological shortcomings and variation in methods
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between studies [26]. For this reason, the scores on each
criterion for all studies are presented in Table 2.
 Efficacy analysis
Owing to the relatively small study populations, clini-
cally relevant differences in outcomes between treat-
ment could remain undetected. Statistical pooling
would have increased the power, but it was decided not
to pool the data and to perform a quantitative analysis,
based on levels of evidence, instead. It is therefore possi-
ble that some smaller differences between treatment
groups might have been missed. However, this does not
seem likely when reviewing the data from the trials, be-
cause the differences that were not statistically signifi-
cant were mostly so small that they were also not clini-
cally relevant.
The strength of the evidence for the efficacy of an in-
tervention is partly based on the methodological quality
of the studies. The difference between high and low
quality studies in this review was based on an arbitrarily
chosen cut-off point, but varying this point had little
influence on the results.
No consensus has yet been reached on how to assess
the strength of the available evidence, and therefore the
levels of evidence used in this review are, to some extent,
arbitrary. It was decided to apply this rating system, be-
cause it has a good face validity, it is simple and explicit
and had already been applied in several reviews on the
effectiveness of conservative treatment options for low
back pain [42, 43].
In a recently published Cochrane review on the effec-
tiveness of local corticosteroid injections, it was con-
cluded that injections result in greater clinical improve-
ment in symptoms after one month, compared to
placebo [29]. This review is comparable to the present
review, and the results are based on two (high quality)
trials that were also included in this review. The only dif-
ference is that no rating system for levels of evidence was
used, but that the data were pooled (despite the fact that
one trial compares a carpal tunnel injection proximal to
the carpal tunnel with placebo and the other trial an in-
jection into the carpal tunnel with an intramuscular in-
jection). In a narrative review on the clinical manage-
ment of (work-related) CTS [17], the conclusion was that
there is limited evidence that steroid injections and
pyridoxine are associated with pain reduction.However,
the authors also state that this conclusion is preliminary
because of the small number of controlled studies. This
review differs from the present review in several ways:
not only RCTs, but also other study designs were in-
cluded, the methodological quality of the studies was
not assessed and no rating system for the strength of the
available evidence was applied.
The American Academy of Neurology recommends
wrist splints, NSAIDs, diuretics and, at a later stage,
steroid injections for the treatment of CTS. These meth-
ods of treatment are merely options, which implies that
the recommendations are based on inconclusive or con-
flicting evidence or opinions [2]. According to the pre-
sent review only steroid injections in, or proximal to the
carpal tunnel might be effective in the short-term and
ultrasound in the long-term, but the evidence is limited.
Therefore, in the opinion of the authors, no clear recom-
mendations can yet be made.
Conclusions
There is still little known about the efficacy of most con-
servative treatment options for CTS. To establish strong
evidence, there is a clear need for more high quality tri-
als, not only focusing on the short-term, but also on the
long-term effects, and providing adequate data.
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